Decision Sheet – Biopure Corporation Marketing Objective – Whether to launch Oxyglobin now or delay it till the approval of Hemopure. If yes‚ then devise a marketing plan for Oxyglobin. Options – 1. Launch Oxyglobin in the market immediately. 2. Defer the launch of Oxyglobin now till Hemopure release. Recommendation – Biopure Corporation should immediately launch Oxyglobin priced at $200. Rationale – Applying SWOT Analysis to the situation: Strengths 1. FDA approval has already come
Premium Blood Blood transfusion Marketing
Biopure Overview: * Biopure Corporation is a privately owned biopharmaceutical firm specializing in the ultrapurification of proteins for human and veterinary use. * It is one of the three legitimate contenders in the emerging field of “blood substitutes”. * Their products Oxyglobin and Hemopure are blood substitutes for the animal and the human market respectively. * Oxyglobin has just received final FDA approval for commercial release and is ready for launch. Hemopure would soon
Premium Blood Blood transfusion
Biopure Corporation Written Case Study I. Current Situation Audit A. Issue Oxyglobin and Hemopure are two blood substitutes that Biopure Corporation was developing. Oxyglobin was recently approved by the FDA for veterinary use while Hemapure is estimated to be approved in two years for human use. If Oxyglobin is launched it will be the first blood substitute for the veterinary market a small and price sensitive market. There is a perceived risk by Ted Jacobs‚ the VP of Human Clinical Trials
Free Blood Blood transfusion
Biopure Case Analysis Group 1‚ Section B The analysis deals with the Target Markets and their different segments for the two products of Biopure Corporation‚ namely Oxyglobin and Hemopure. Oxyglobin -‐ Used as a substitute for blood transfusion in dogs. -‐ Target market is 30% of all the
Premium
Biopure Case Study Executive Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure‚ directed to the human market and Oxyglobin‚ for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes both products from other “hemoglobin-based” blood substitutes is the fact that they are “bovine-sourced” as opposed to “human-sourced”‚ i.e. they are derived from
Free Blood Blood transfusion
Executive Summary Biopure Corporation was established in 1984 and is a privately owned pharmaceutical firm. They are trying to launch two new products: Hemopure (human market) and Oxyglobin (veterinary market). They are the only company aggressively engaged in the development of blood substitutes for the vet market. Biopure has invested $200M in the development of said blood substitutes. They currently don’t have any revenues with little to no debt and financing of $50M to support these operations
Premium Health care Net present value Medicine
+ Biopure Corporation Case Analysis Back Bay Xue Yang + Agenda 1. Current Situation 2. SWOT Analysis 3. Quantitative Analysis 4. Recommendations + Current SituationBiopure Corporation The main objectives of Biopure Corporation is blood substitutes development There are 2 products: Oxyglobin and Hemopure. Oxyglobin is targeting at veterinary market and Hemopure is targeting at human market The company has spent $200 million on R&D of Hemopure Oxyglobin has already approved
Premium Variable cost Blood Marketing
Course: Biopure Corporation 1. Decision: Biopure should launch Oxyglobin at a price of $200 immediately in the market. The early introduction of Oxyglobin may jeopardize the ability to set a high price for Hemopure‚ but the benefits of introduction will outweigh the risks. 2. Recommendation: Biopure should price Oxyglobin at $200 per unit. At the same time‚ it should enlarge the production capacity as soon as possible to satisfy the potential market demand for Hempure. As for the distribution
Premium Blood Blood transfusion
BIOPURE Corporation. 1. Give your best estimate of the sizes of Biopure’s market‚ potential market‚ and what you recommend as the target market in the animal market? Do the same for the human blood market? Who are these people (or animals)? Since the definitions of these different markets can be vague‚ it may be useful to operationalize these concepts in terms of circles on a target which represent the likelihood of being a customer and when they should be targeted by the company. Thus‚ the “target
Free Blood Blood transfusion Surgery
Andrew Walters 3/22/12 Biopure Biopure Corporation specializes in blood substitutes for transfusion patients‚ both in the veterinary market and the human market. However‚ in 1998‚ Biopure faced the monumental decision of whether to begin selling Oxyglobin‚ a blood substitute‚ to the veterinary market or to wait until Hemoglobin‚ a blood substitute for the human market‚ became available for sale. The problem is whether or not the company should launch Oxyglobin before Hemoglobin is FDA-approved
Premium Blood transfusion Blood